logo-loader
viewOpen Orphan PLC

Open Orphan says hVIVO to collaborate with HIC-Vac and the Wellcome Trust to set standards for the manufacture of human challenge agents

“We are proud to have been selected to work alongside HIC-Vac and the Wellcome Trust to lead the consortium on this important and much-needed guidelines,” said chairman Cathal Friel

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) said its hVIVO division has been selected to lead a consortium that has been tasked with generating regulatory style guidelines on the manufacture of human challenge agents for use in controlled human infection studies.

In doing so it will collaborate with HIC-Vac, an international network of researchers developing human infection challenge studies to accelerate the development of vaccines against pathogens, and the international medical charity, the Wellcome Trust.

hVIVO will help set international standards for challenge agent manufacture and storage, building on the current World Health Organisation guidelines.

The consortium is also working on guidance that on good manufacturing practice that stops short of GMP certification. Open Orphan said this will allow flexibility to manufacture challenge agents outside of GMP-certified premises, but with guidance to ensure safety, quality and consistency are maintained.

“We are proud to have been selected to work alongside HIC-Vac and the Wellcome Trust to lead the consortium on this important and much-needed guidelines,” said Open Orphan chairman Cathal Friel in a statement.

“hVIVO is at the forefront of human challenge studies and has world-leading capabilities, this collaboration is recognition of the work we do in the scientific community."

Quick facts: Open Orphan PLC

Price: 25 GBX

AIM:ORPH
Market: AIM
Market Cap: £166.99 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan present at the Proactive One2one virtual investment forum

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual October Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical...

1 week, 1 day ago

2 min read